This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Radhakrishnan, S. K. Articles by Gartel, A. L. Search for Related Content PubMed PubMed Citation Articles by Radhakrishnan, S. K. Articles by Gartel, A. L.

Identification of a Chemical Inhibitor of the Oncogenic Transcription Factor Forkhead Box M1

Departments of ¹ Medicine, ² Microbiology and Immunology, and ³ Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois

Requests for reprints: Andrei L. Gartel, Department of Medicine, University of Illinois at Chicago, Room 1041, 840, South Wood Street, Chicago, IL 60612. Phone: 312-996-1855; Fax: 312-996-8697; E-mail: agartel{at}uic.edu.

The oncogenic transcription factor forkhead box M1 (FoxM1) is overexpressed in a number of different carcinomas, whereas its expression is turned off in terminally differentiated cells. For this reason, FoxM1 is an attractive target for therapeutic intervention in cancer treatment. As a first step toward realizing this goal, in this study, using a high-throughput, cell-based assay system, we screened for and isolated the antibiotic thiazole compound Siomycin A as an inhibitor of FoxM1. Interestingly, we observed that Siomycin A was able to down-regulate the transcriptional activity as well as the protein and mRNA abundance of FoxM1. Consequently, we found that the downstream target genes of FoxM1, such as Cdc25B, Survivin, and CENPB, were repressed. Also, we observed that consistent with earlier reports of FoxM1 inhibition, Siomycin A was able to reduce anchorage-independent growth of cells in soft agar. Furthermore, we found that Siomycin A was able to induce apoptosis selectively in transformed but not normal cells of the same origin. Taken together, our data suggest that FoxM1 inhibitor Siomycin A could represent a useful starting point for the development of anticancer therapeutics. (Cancer Res 2006; 66(19): 9731-5)

This article has been cited by other articles:

				U. B. McGovern, R. E. Francis, B. Peck, S. K. Guest, J. Wang, S. S. Myatt, J. Krol, J. M-M. Kwok, A. Polychronis, R. C. Coombes, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer Mol. Cancer Ther., March 1, 2009; 8(3): 582 - 591. [Abstract] [Full Text] [PDF]

				J. M-M. Kwok, S. S. Myatt, C. M. Marson, R. C. Coombes, D. Constantinidou, and E. W-F. Lam Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression Mol. Cancer Ther., July 1, 2008; 7(7): 2022 - 2032. [Abstract] [Full Text] [PDF]

				V. Petrovic, R. H. Costa, L. F. Lau, P. Raychaudhuri, and A. L. Tyner FoxM1 Regulates Growth Factor-induced Expression of Kinase-interacting Stathmin (KIS) to Promote Cell Cycle Progression J. Biol. Chem., January 4, 2008; 283(1): 453 - 460. [Abstract] [Full Text] [PDF]